why choose us

First received: December 14, 2022

Clinical Trial: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Study Status: Completed

Recruit Status: RECRUITING

Condition: B-cell Non-Hodgkins Lymphoma (B-NHL)

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecif

Brief Summary: The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab.The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs).The study is looking at several other research questions, including:What side effects may happen from taking the study drugsHow much study drug…

Read more